Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 42321502 · doi:10.1038/s41366-026-02118-y
What was done
Systematic review and meta-analysis of randomized controlled trials (RCTs) identified via PubMed, Embase, and LILACS up to March 2025. The review evaluated patients with obesity treated with GLP-1 receptor agonists (GLP1-RA) at obesity doses versus placebo. Using a random-effects model, the authors assessed lean mass as a proportion of total weight, absolute and relative changes in lean mass, and adverse effects.
What was found
Seven RCTs with 821 patients were included. GLP1-RA significantly increased lean mass as a proportion of total weight by 1.81% (95% CI: 1.1 to 2.52; p < 0.00001; I² = 7%). However, GLP1-RA led to a significant decrease in absolute lean mass of -1.74 kg (95% CI: -3.04 to -0.45; p < 0.00001; I² = 98%) and in the percentage of lean mass by -3.06% (95% CI: -5.10 to -1.02; p < 0.00001; I² = 98%). Semaglutide had an absolute lean mass loss of -5.44 kg (95% CI: -7.07 to -3.81; p < 0.00001).
Why it matters
This meta-analysis demonstrates that while GLP-1 receptor agonists reduce absolute lean mass during weight loss, the proportion of lean mass relative to total body weight increases.
Limits
The total sample size was small across only 7 trials (821 patients). There was extreme statistical heterogeneity (I² = 98%) for absolute and percentage lean mass changes. Functional muscle strength, long-term maintenance, specific body composition measurement modalities, and adverse effects were not reported in the abstract.
Cited by
- supports GLP-1 medications do not inherently consume or break down muscle and bone tissue directly; any loss of lean mass is due to general weight loss.